Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding
January 6, 2019
Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346. The study will run in Canada and is expected to conclude in December 2018.
Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma
August 15, 2018
SOUTHBOROUGH, MA – August 15, 2018 – Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States.